Cladribine Regimen for Treating Progressive Multiple Sclerosis, Merck Patent GmbH, EP3713582A1
Summary
Merck Patent GmbH has been granted patent protection for a cladribine-based regimen for treating progressive forms of multiple sclerosis. The patent application EP3713582A1 was published on April 15, 2026, designating 32 states including major European markets. Inventors include DOTZAUER, Matthias and DANGOND, Fernando. The patent claims cover pharmaceutical compositions and methods using cladribine (A61K 31/7076) for neurological applications (A61P 25/00).
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
The EPO published patent application EP3713582A1 for Merck Patent GmbH, covering a cladribine treatment regimen for progressive multiple sclerosis. The patent specifies pharmaceutical compositions containing cladribine (A61K 31/7076) formulated for neurological applications (A61P 25/00), including solid dosage forms (A61K 9/20, A61K 9/48) with cyclodextrin excipients (A61K 47/40).
Affected parties include Merck Patent GmbH, which gains exclusive rights to manufacture and commercialize cladribine-based treatments for progressive MS in designated states, and competitors seeking to develop similar treatments will need to design around this patent. Pharmaceutical companies, researchers, and healthcare providers working in the multiple sclerosis therapeutic space should review their programs for potential infringement exposure.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CLADRIBINE REGIMEN FOR USE INTREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
Publication EP3713582A1 Kind: A1 Apr 15, 2026
Applicants
Merck Patent GmbH
Inventors
DOTZAUER, Matthias, DANGOND, Fernando
IPC Classifications
A61K 31/7076 20060101AFI20190531BHEP A61P 25/00 20060101ALI20190531BHEP A61K 47/40 20060101ALI20190531BHEP A61K 9/20 20060101ALI20190531BHEP A61K 9/48 20060101ALI20190531BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.